ARTCLINE Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $9.8M

  • Investors
  • 1

ARTCLINE General Information

Description

Operator of an immune cell-based extracorporeal therapy intended for treating sepsis. The company provides allogeneic immune cell therapy, removal of inflammatory substances, and production of immunological messengers, enabling healthcare providers to treat sepsis, reduce mortality rates, and improve patient outcomes in intensive care units.

Contact Information

Website
www.artcline.de
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Schillingallee 68
  • 18057 Rostock
  • Germany
+49 0381
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Corporate Office
  • Schillingallee 68
  • 18057 Rostock
  • Germany
+49 0381

ARTCLINE Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ARTCLINE Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 09-Sep-2026 $9.8M Completed Clinical Trials - General
1. Later Stage VC 25-Mar-2024 Completed Clinical Trials - General
To view ARTCLINE’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ARTCLINE Patents

ARTCLINE Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4154925-A1 Immune cell treatment Inactive 22-Sep-2021
EP-4404991-A1 Immune cell treatment Pending 22-Sep-2021
US-20250144279-A1 Immune cell treatment Pending 22-Sep-2021
WO-2023046874-A1 Immune cell treatment Inactive 22-Sep-2021
DE-102012209673-A1 A method for producing a leukocyte preparation and leukocyte preparation Inactive 08-Jun-2012 A61K35/16
To view ARTCLINE’s complete patent history, request access »

ARTCLINE Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ARTCLINE Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern Venture Capital Minority
To view ARTCLINE’s complete investors history, request access »

ARTCLINE FAQs

  • When was ARTCLINE founded?

    ARTCLINE was founded in 2007.

  • Where is ARTCLINE headquartered?

    ARTCLINE is headquartered in Rostock, Germany.

  • What is the size of ARTCLINE?

    ARTCLINE has 17 total employees.

  • What industry is ARTCLINE in?

    ARTCLINE’s primary industry is Biotechnology.

  • Is ARTCLINE a private or public company?

    ARTCLINE is a Private company.

  • What is ARTCLINE’s current revenue?

    The current revenue for ARTCLINE is .

  • How much funding has ARTCLINE raised over time?

    ARTCLINE has raised $14.5M.

  • Who are ARTCLINE’s investors?

    Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern has invested in ARTCLINE.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process